Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope Orange County, shared on X:
“What NEST taught us.
Lesson 1: Time
In NEST2, I’m glad we did not add another dose of the CTLA-4 inhibitor BOT in the amendment.
More time before surgery – 8 weeks instead of 4. More time to brew.
Pathologic responses deepened and nearly doubled.”
Title: Neoadjuvant Botensilimab/Balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial
Authors: Manish A. Shah, Erika Hissong, Mehraneh D. Jafari, Pashtoon Murtaza Kasi, Maider Astorkia, Sahrish Khan, Casey Owens, Zhengming Chen, Heather Yeo, Fabio Socciarelli, Sandipto Sarkar, Alana Nguyen, Despina Siolas, Allyson Ocean, Kelly Garrett, Lea Lowenfeld, Alessio Pigazzi, Preethi Guniganti, Sanjay Patel, Doron Betel, Manuel Hidalgo․
You can also read: Phase 2 NEST Trial: Neoadjuvant BOT/BAL in Localized Colon Cancer
